Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 4, Pages (October 2018)

Similar presentations


Presentation on theme: "Volume 4, Pages (October 2018)"— Presentation transcript:

1 Volume 4, Pages 32-42 (October 2018)
Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma  Young-Woo Jeon, Hee-Jung Yang, Byung-Ock Choi, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Suk-Woo Yang, Seok-Goo Cho  EClinicalMedicine  Volume 4, Pages (October 2018) DOI: /j.eclinm Copyright © Terms and Conditions

2 Fig. 1 Therapeutic strategy and therapeutic responses after first-line therapy. All patients diagnosed with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) were classified according to combined Ann Arbor stage and tumor node metastasis (TNM) staging systems, and then an appropriate frontline therapeutic approach was selected for each patient. EClinicalMedicine 2018 4, 32-42DOI: ( /j.eclinm ) Copyright © Terms and Conditions

3 Fig. 2 Survival outcomes according to staging systems in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML). Kaplan–Meier estimates of overall survival (A), progression-free survival (B), and cumulative incidence of relapse (C) according to the TNM staging system. Kaplan–Meier estimates of overall survival (D), progression-free survival (E), and cumulative incidence of relapse (F) according to the Ann Arbor staging system. EClinicalMedicine 2018 4, 32-42DOI: ( /j.eclinm ) Copyright © Terms and Conditions

4 Fig. 3 Survival outcomes for chemotherapy alone of advanced primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML). (A) Cumulative incidences of relapses according to TNM staging of the chemotherapy group. (B) Progression-free survival according to rituximab usage in the beyond T2N0M0 chemotherapy group. EClinicalMedicine 2018 4, 32-42DOI: ( /j.eclinm ) Copyright © Terms and Conditions

5 Fig. 4 Survival outcomes after radiotherapy and rituximab-containing chemotherapy. Kaplan–Meier estimates of overall survival (A) and progression-free survival (B) between frontline radiotherapy and primary rituximab-containing chemotherapy. EClinicalMedicine 2018 4, 32-42DOI: ( /j.eclinm ) Copyright © Terms and Conditions


Download ppt "Volume 4, Pages (October 2018)"

Similar presentations


Ads by Google